8-K: Cabaletta Bio Advances Autoimmune CAR T-Cell Therapy, Targets 2027 BLA

Cabaletta Bio provides an updated corporate presentation highlighting significant progress in its rese-cel CAR T-cell therapy program for autoimmune diseases, including FDA alignment for registrational trials and a planned 2027 BLA submission for myositis.

Summary

• Cabaletta Bio posted an updated corporate presentation dated September 2025, detailing progress on its rese-cel (CABA-201) program.
• Rese-cel is an autologous CD19-CAR T-cell therapy being developed for various autoimmune diseases.
• The company has over 70 clinical sites recruiting across six indications: myositis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), myasthenia gravis (MG), multiple sclerosis (MS), and pemphigus vulgaris (PV).
• FDA alignment has been achieved for open-label single-arm evaluation of registrational cohorts in the RESET-Myositis trial, targeting approximately 15 patients in each of two sub-type specific cohorts (DM/ASyS and IMNM).
• A Biologics License Application (BLA) submission for myositis is planned for 2027.
• Clinical data in the vast majority of dosed patients demonstrates transformative clinical responses off medications, with approximately 90% experiencing no Cytokine Release Syndrome (CRS) or only transient fever (Grade 1 CRS) and approximately 90% having no Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
• The company anticipates FDA alignment on pivotal trial design for SLE/Lupus Nephritis (LN) and scleroderma in the second half of 2025, and for MG in the first half of 2026.
• Enrollment in Phase 1/2 RESET trial cohorts is rapidly completing, with 65 patients actively enrolled and 38 dosed as of August 27, 2025.
• Cabaletta Bio is advancing a whole blood manufacturing program to eliminate the need for apheresis and is progressing with Cellares for automated manufacturing.
• Initial clinical data from the RESET-PV trial (without preconditioning) will be presented at ESGCT in October 2025.

Sentiment

Score: 8

Explanation: The presentation highlights significant clinical progress, regulatory alignment, and a clear path to BLA submission for myositis, indicating strong operational execution and promising therapeutic potential. While some adverse events occurred, the overall safety profile and efficacy data are encouraging for a novel cell therapy addressing high unmet needs in autoimmune diseases.

Positives

• FDA alignment on registrational trial design for myositis, enabling an accelerated regulatory path with a planned BLA submission in 2027.
• Transformative clinical responses observed in the vast majority of dosed patients across indications, including potential for drug-free remission.
• Favorable safety profile with approximately 90% of patients experiencing no CRS or only Grade 1 CRS, and approximately 90% having no ICANS.
• Expansion of the clinical network with 73 recruiting sites in the US and Europe, indicating strong operational execution.
• Advancement of manufacturing innovations, including a whole blood process and automation with Cellares, aimed at improving patient experience and scalability.
• Multiple near-term catalysts with upcoming data presentations at ESGCT (October 9), ACR (October 24-29), and AANEM (October 29) in 2025.
• FDA Fast Track Designation received in dermatomyositis, SLE, lupus nephritis, systemic sclerosis, and multiple sclerosis, and Regenerative Medicine Advanced Therapy (RMAT) received in myositis, SLE, and LN.
• Deep B cell depletion observed in lymph node biopsy in an SSc patient (SSc-Skin-1), consistent with deep B cell depletion in circulation.

Negatives

• One IMNM patient (IMNM-2) showed 'no change' in TIS response and persistently elevated HMGCR antibodies, suggesting potential limitations in certain patient subsets or disease mechanisms.
• One SSc patient (SSc-Skin-2) experienced Grade 3 ICANS and Grade 1 neutropenic fever as related serious adverse events.
• One SLE patient (LN-1) experienced Grade 4 Pancytopenia as a related serious adverse event.
• One SLE patient (SLE-1) required cyclosporine therapy for a non-SLE-related, non-rese-cel-related safety event (macrophage activation syndrome) at Week 40.

Risks

• Risks related to the success, cost, and timing of development activities and clinical trials.
• Risks related to the ability to demonstrate sufficient evidence of safety, efficacy, and tolerability in clinical trials.
• The risk that results observed with similarly-designed constructs are not indicative of the results sought with rese-cel.
• The risk that signs of biologic activity or persistence may not inform long-term results.
• Risks related to clinical trial site activation or enrollment rates that are lower than expected.
• Risks that modifications to trial design or approach may not have the intended benefits and that the trial design may need to be further modified.
• The ability to protect and maintain intellectual property position.
• Risks related to relationships with third parties, including suppliers and manufacturers.
• Uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to product candidates.
• The ability to retain and recognize the intended incentives conferred by any regulatory designations.
• Risks related to regulatory filings and potential clearance.
• The risk that any one or more product candidates will not be successfully developed and commercialized.
• The risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies.
• Risks related to volatile market and economic conditions.
• The ability to fund operations and continue as a going concern.

Future Outlook

The company anticipates FDA alignment on pivotal trial designs for SLE/LN and scleroderma in the second half of 2025, and for MG in the first half of 2026. A Biologics License Application (BLA) submission for myositis is planned for 2027. Enrollment in myositis registrational cohorts is expected to initiate in 2025, with completion of dosing in multiple disease-specific cohorts also anticipated in 2025. The company is also working towards CMC commercial supply readiness and innovation, including a commercial process implemented for Lupus, SSc, and MG.

Management Comments

• We believe rese-cel has the potential to provide drug-free, durable transformative clinical responses, through an immune reset, including the potential for achieving drug-free remission in patients with refractory myositis.
• We plan to leverage increasing clinical data and a unique development program for rese-cel.
• We believe the expectations reflected in such forward-looking statements are reasonable.

Industry Context

The filing positions Cabaletta Bio as a key player in the rapidly evolving field of targeted cellular therapies (CAR T-cells) for autoimmune diseases. The company is adapting the successful CAR T-cell technology from oncology to address significant unmet needs in autoimmune conditions, aiming for 'immune reset' and drug-free remission, which represents a potential paradigm shift from current chronic immunosuppressive treatments. The focus on CD19 targeting aligns with established mechanisms for B-cell depletion in autoimmunity, indicating a scientifically grounded approach.

Comparison to Industry Standards

• Rese-cel's binder demonstrates similar in vitro and in vivo activity to the academic FMC63 binder, which has been utilized in academic studies for autoimmune diseases.
• The weight-based dose of rese-cel is consistent with doses used in academic studies.
• B cell depletion observed with rese-cel is consistent with academic studies in autoimmune disease, showing CD19-CAR T cell therapy achieves deeper depletion than monoclonal antibodies (mAbs).
• The safety profile, characterized by low rates of severe CRS and ICANS, is presented as favorable compared to the higher rates often seen with approved oncology CAR T products.
• Cabaletta Bio's clinical site footprint, with 73 recruiting sites in the US and Europe, is described as 'industry-leading' when compared to other companies actively recruiting for autoimmune cell therapy trials under company-sponsored INDs.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress, regulatory milestones, and potential for future commercialization, which could increase company valuation.
• Patients: Highly positive impact as rese-cel offers potential for drug-free, durable transformative clinical responses in severe autoimmune diseases with high unmet needs.
• Employees: Positive impact from continued progress and potential for growth in a leading biotechnology company.
• Regulatory Authorities: Engagement and alignment with FDA on trial designs demonstrate adherence to regulatory pathways.

Next Steps

• Present late-breaking clinical trial data for rese-cel (1st dose cohort without preconditioning) at ESGCT (October 9, 2025).
• Present complete Phase 1/2 RESET-Myositis data and interim updates from RESET-SSc & RESET-SLE at ACR (October 24-29, 2025).
• Present initial clinical data from the RESET-MG trial at AANEM (October 29, 2025).
• Align with FDA on pivotal trial designs for SLE/LN and scleroderma in 2H 2025.
• Initiate enrollment in myositis registrational cohorts in 2025.
• Align with FDA on pivotal trial design for MG in 1H 2026.
• Achieve CMC commercial supply readiness and innovation.
• Submit BLA for myositis in 2027.

Key Dates

Recommendation

The filing details substantial progress in a high-potential therapeutic area (CAR T for autoimmunity), including FDA alignment for registrational trials and a clear timeline for BLA submission. The clinical data presented shows compelling efficacy with a manageable safety profile, addressing significant unmet medical needs. The company's strategic execution, expanding clinical network, and manufacturing innovations further de-risk the development path, making it an attractive investment.

Keywords

Cabaletta Bio, rese-cel, CABA-201, CAR T-cell therapy, autoimmune disease, myositis, systemic lupus erythematosus, lupus nephritis, systemic sclerosis, myasthenia gravis, multiple sclerosis, pemphigus vulgaris, clinical trials, FDA, BLA, RMAT, Fast Track, cell therapy, immunology, biotechnology, drug development